Credit Suisse’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | $2.1M | Sell |
98,455
-64,557
| -40% | -$1.39M | ﹤0.01% | 1827 |
|
|
2023
Q4 | $3.12M | Sell |
163,012
-22,828
| -12% | -$395K | ﹤0.01% | 1618 |
|
|
2023
Q3 | $2.98M | Buy |
185,840
+13,154
| +8% | +$250K | ﹤0.01% | 1584 |
|
|
2023
Q2 | $4M | Buy |
172,686
+23,723
| +16% | +$518K | ﹤0.01% | 1480 |
|
|
2023
Q1 | $3.46M | Sell |
148,963
-31,981
| -18% | -$650K | ﹤0.01% | 1546 |
|
|
2022
Q4 | $2.63M | Buy |
180,944
+55,193
| +44% | +$1.03M | ﹤0.01% | 1729 |
|
|
2022
Q3 | $2.4M | Buy |
125,751
+863
| +0.7% | +$19.8K | ﹤0.01% | 1747 |
|
|
2022
Q2 | $2.27M | Sell |
124,888
-15,152
| -11% | -$315K | ﹤0.01% | 1825 |
|
|
2022
Q1 | $3.53M | Sell |
140,040
-36,717
| -21% | -$940K | ﹤0.01% | 1700 |
|
|
2021
Q4 | $4.88M | Buy |
176,757
+43,678
| +33% | +$1.27M | ﹤0.01% | 2042 |
|
|
2021
Q3 | $4.3M | Buy |
133,079
+7,418
| +6% | +$246K | ﹤0.01% | 2192 |
|
|
2021
Q2 | $3.84M | Sell |
125,661
-9,178
| -7% | -$265K | ﹤0.01% | 2308 |
|
|
2021
Q1 | $4.11M | Sell |
134,839
-55,716
| -29% | -$1.58M | ﹤0.01% | 2239 |
|
|
2020
Q4 | $3.77M | Sell |
190,555
-129,735
| -41% | -$2.1M | ﹤0.01% | 2332 |
|
|
2020
Q3 | $4.18M | Buy |
320,290
+67,574
| +27% | +$855K | ﹤0.01% | 1912 |
|
|
2020
Q2 | $2.87M | Buy |
252,716
+136,560
| +118% | +$1.94M | ﹤0.01% | 2101 |
|
|
2020
Q1 | $1.66M | Sell |
116,156
-10,737
| -8% | -$227K | ﹤0.01% | 2262 |
|
|
2019
Q4 | $3.46M | Buy |
126,893
+63,963
| +102% | +$1.76M | ﹤0.01% | 2166 |
|
|
2019
Q3 | $1.8M | Buy |
62,930
+2,875
| +5% | +$83.8K | ﹤0.01% | 2539 |
|
|
2019
Q2 | $1.67M | Buy |
60,055
+3,546
| +6% | +$100K | ﹤0.01% | 2584 |
|
|
2019
Q1 | $1.88M | Sell |
56,509
-194,715
| -78% | -$5.93M | ﹤0.01% | 2419 |
|
|
2018
Q4 | $7.3M | Buy |
251,224
+66,111
| +36% | +$2.38M | 0.01% | 1346 |
|
|
2018
Q3 | $8.52M | Buy |
185,113
+117,174
| +172% | +$5.21M | 0.01% | 1355 |
|
|
2018
Q2 | $2.54M | Sell |
67,939
-158,096
| -70% | -$5.34M | ﹤0.01% | 2252 |
|
|
2018
Q1 | $6.68M | Buy |
226,035
+95,719
| +73% | +$3.24M | 0.01% | 1514 |
|
|
2017
Q4 | $4.48M | Buy |
130,316
+10,135
| +8% | +$342K | ﹤0.01% | 1850 |
|
|
2017
Q3 | $4.35M | Sell |
120,181
-47,777
| -28% | -$1.36M | ﹤0.01% | 1881 |
|
|
2017
Q2 | $4.34M | Sell |
167,958
-59,447
| -26% | -$1.26M | ﹤0.01% | 1727 |
|
|
2017
Q1 | $4.37M | Sell |
227,405
-62,703
| -22% | -$1.11M | ﹤0.01% | 1755 |
|
|
2016
Q4 | $4.84M | Sell |
290,108
-18,868
| -6% | -$341K | ﹤0.01% | 1673 |
|
|
2016
Q3 | $6.36M | Sell |
308,976
-66,892
| -18% | -$1.7M | 0.01% | 1478 |
|
|
2016
Q2 | $11.5M | Buy |
375,868
+62,996
| +20% | +$2.19M | 0.01% | 1067 |
|
|
2016
Q1 | $11.7M | Buy |
312,872
+89,270
| +40% | +$3.36M | 0.01% | 1021 |
|
|
2015
Q4 | $9.65M | Sell |
223,602
-13,100
| -6% | -$553K | 0.01% | 1165 |
|
|
2015
Q3 | $8.87M | Sell |
236,702
-97,970
| -29% | -$3.48M | 0.01% | 1186 |
|
|
2015
Q2 | $11.4M | Buy |
334,672
+33,539
| +11% | +$1.14M | 0.01% | 1163 |
|
|
2015
Q1 | $10.7M | Buy |
301,133
+80,653
| +37% | +$2.89M | 0.01% | 1157 |
|
|
2014
Q4 | $7.51M | Buy |
220,480
+73,076
| +50% | +$2.59M | 0.01% | 1469 |
|
|
2014
Q3 | $5.69M | Buy |
147,404
+40,142
| +37% | +$1.5M | ﹤0.01% | 1659 |
|
|
2014
Q2 | $4.17M | Sell |
107,262
-18,311
| -15% | -$681K | ﹤0.01% | 2116 |
|
|
2014
Q1 | $4.29M | Sell |
125,573
-334,895
| -73% | -$10.4M | ﹤0.01% | 1892 |
|
|
2013
Q4 | $9.66M | Buy |
460,468
+214,252
| +87% | +$5.42M | 0.01% | 1302 |
|
|
2013
Q3 | $5.79M | Sell |
246,216
-28,982
| -11% | -$823K | 0.01% | 1520 |
|
|
2013
Q2 | $7.39M | Buy |
+275,198
| New | +$7.98M | 0.01% | 1322 |
|
Other funds holding MYGN
CCM
GCM
Credit Suisse's MYGN Position: Q1 2024 in Review
Credit Suisse reduced its Myriad Genetics (MYGN) stake by 40% in Q1 2024, selling an estimated $1.39M and leaving 98,455 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1827.
Credit Suisse first reported a position in MYGN in Q2 2013 and has held it in 44 quarters since. The position peaked at $11.7M in Q1 2016. 186 funds tracked by Wall St. Rank hold MYGN as of Q1 2024.
- Credit Suisse held 98,455 shares of Myriad Genetics worth $2.1M as of Q1 2024.
- Credit Suisse sold 64,557 Myriad Genetics shares in Q1 2024, an estimated $1.39M.
- Myriad Genetics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #1827 holding.
- Credit Suisse first reported a position in Myriad Genetics in Q2 2013 and has held it in 44 quarters since.
- Credit Suisse's Myriad Genetics position peaked at $11.7M in Q1 2016.
- 186 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2024.
Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.